Radioresistance in non-small cell lung cancer (NSCLC) presents a major barrier to effective treatment. This study explores the molecular mechanisms underlying this resistance, focusing on the heterogeneous nuclear ribonucleoprotein A2B1/hepatoma-derived growth factor/pleiotrophin (HNRNPA2B1/HDGF/PTN) signaling pathway and its role in autophagy-dependent ferroptosis regulation. Our aim is to uncover how this pathway contributes to tumor cell survival under radiotherapy stress, thereby identifying potential therapeutic targets to overcome radioresistance.
Results:
We developed radiotherapy-resistant lung cancer cell lines and assessed their proliferation and migration capabilities through Cell Counting Kit-8 and Transwell assays, respectively. Single-cell RNA sequencing revealed significant differences in gene expression profiles between radioresistance and radiation-sensitive cells. Functional studies, including immunofluorescence, flow cytometry, and biochemical staining, confirmed that radioresistance was associated with enhanced autophagy and altered ferroptosis. Furthermore, HNRNPA2B1 knockdown reduced the expression of Ki67 and proliferating cell nuclear antigen, markers of proliferation, in a mouse tumor model. In addition, modulation of HNRNPA2B1 affected protein interactions and N6-methyladenosine RNA modifications, as demonstrated by reverse transcription–quantitative polymerase chain reaction, Western blot, and methylation RNA immunoprecipitation–quantitative PCR.
Innovation:
This study provides new insights into how the HNRNPA2B1/HDGF/PTN pathway promotes radioresistance by influencing autophagy-dependent ferroptosis. This mechanism represents a potential vulnerability that could be therapeutically targeted to improve radiotherapy efficacy in lung cancer.
Conclusion:
Our findings demonstrate that the HNRNPA2B1/HDGF/PTN signaling pathway plays a crucial role in sustaining radioresistant phenotypes by modulating autophagy and ferroptosis. Targeting this pathway may enhance the therapeutic response in NSCLC, offering a novel strategy to combat treatment resistance. Antioxid. Redox Signal. 43, 189–214.
AlarcónCR, GoodarziH, LeeH, et al.HNRNPA2B1 is a mediator of M6A-Dependent nuclear RNA processing events. Cell, 2015; 162(6):1299–1308; doi: 10.1016/j.cell.2015.08.011
BatenburgMCT, BartelsM, MaarseW, et al.Factors associated with late local radiation toxicity after post-operative breast irradiation. Breast J, 2022; 2022:6745954; doi: 10.1155/2022/6745954
5.
ChanC, LangS, RowbottomC, et al.; IASLC Advanced Radiation Technology Committee. Intensity-Modulated radiotherapy for lung cancer: Current status and future developments. J Thorac Oncol, 2014; 9(11):1598–1608; doi: 10.1097/jto.0000000000000346
6.
ChenY, GaoM, HuangZ, et al.SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: A focus on the mechanisms, advances, and future challenges. J Hematol Oncol, 2020; 13(1):105; doi: 10.1186/s13045-020-00940-z
7.
ChenQ, ZhengW, GuanJ, et al.SOCS2-Enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma. Cell Death Differ, 2023; 30(1):137–151; doi: 10.1038/s41418-022-01051-7
8.
ChenY, ZhouY, FengX, et al.Targeting FBXO22 enhances radiosensitivity in non-small cell lung cancer by inhibiting the FOXM1/Rad51 axis. Cell Death Dis, 2024; 15(1):104; doi: 10.1038/s41419-024-06484-1
9.
ChoiHS, KoYS, JinH, et al.Mebendazole increases anticancer activity of radiotherapy in radiotherapy-resistant triple-negative breast cancer cells by enhancing natural killer cell-mediated cytotoxicity. Int J Mol Sci, 2022; 23(24):15493; doi: 10.3390/ijms232415493
10.
DoganE, KaraHG, KosovaB, et al.Targeting apoptosis to overcome chemotherapy resistance. Metastasis, 2022:163–180; doi: 10.3625/5/exon-publications.metastasis.chemotherapy-resistance
11.
DuZ-Y, ShiM-H, JiC-H, et al.Serum pleiotrophin could be an early indicator for diagnosis and prognosis of non-small cell lung cancer. Asian Pac J Cancer Prev, 2015; 16(4):1421–1425; doi: 10.7314/apjcp.2015.16.4.1421
12.
DumaN, Santana-DavilaR, MolinaJR. Non–Small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc, 2019; 94(8):1623–1640; doi: 10.1016/j.mayocp.2019.01.013
13.
FengZ-J, GaoS-B, WuY, et al.Lung cancer cell migration is regulated via repressing growth factor PTN/RPTP β/ζ signaling by menin. Oncogene, 2010; 29(39):5416–5426; doi: 10.1038/onc.2010.282
14.
FoersterEG, MukherjeeT, Cabral-FernandesL, et al.How autophagy controls the intestinal epithelial barrier. Autophagy, 2022; 18(1):86–103; doi: 10.1080/15548627.2021.1909406
15.
FuJ, HaoH, WangS, et al.Marsdenia Tenacissima extract disturbs the interaction between tumor-associated macrophages and non-small cell lung cancer cells by targeting HDGF. J Ethnopharmacol, 2022; 298:115607; doi: 10.1016/j.jep.2022.115607
16.
GaoM, MonianP, PanQ, et al.Ferroptosis is an autophagic cell death process. Cell Res, 2016; 26(9):1021–1032; doi: 10.1038/cr.2016.95
17.
GoodwinCM, WatersAM, KlompJE, et al.Combination therapies with CDK4/6 inhibitors to treat KRAS-Mutant pancreatic cancer. Cancer Res, 2023; 83(1):141–157; doi: 10.1158/0008-5472.can-22-0391
18.
GümüşM, ChenC, IvanescuC, et al.Patient‐reported Outcomes with Cemiplimab Monotherapy for First‐line Treatment of Advanced Non–Small Cell Lung Cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 Study. Cancer, 2023; 129(1):118–129; doi: 10.1002/cncr.34477
19.
HanS, TianZ, TianH, et al.HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer. Cell Death Discov, 2023; 9(1):181; doi: 10.1038/s41420-023-01476-0
20.
HeK, BarsoumianHB, Puebla-OsorioN, et al.Inhibition of STAT6 with antisense Oligonucleotides enhances the systemic antitumor effects of radiotherapy and Anti–PD-1 in metastatic non–small cell lung cancer. Cancer Immunol Res, 2023; 11(4):486–500; doi: 10.1158/2326-6066.cir-22-0547
21.
HouG, LiJ, LiuW, et al.Mesenchymal stem cells in radiation-induced lung injury: From mechanisms to therapeutic potential. Front Cell Dev Biol, 2022; 10:1100305; doi: 10.3389/fcell.2022.1100305
22.
HuT-H, WuJ-C, HuangS-T, et al.HDGF stimulates liver tumorigenesis by enhancing Reactive oxygen species generation in mitochondria. J Biol Chem, 2023; 299(11):105335; doi: 10.1016/j.jbc.2023.105335
23.
HuangW-M, LiZ-X, WuY-H, et al.M6A Demethylase FTO renders radioresistance of nasopharyngeal carcinoma via promoting OTUB1-Mediated anti-ferroptosis. Transl Oncol, 2023; 27:101576; doi: 10.1016/j.tranon.2022.101576
24.
HuangH, WengH, SunW, et al.Recognition of RNA N6-Methyladenosine by IGF2BP proteins enhances MRNA stability and translation. Nat Cell Biol, 2018; 20(3):285–295; doi: 10.1038/s41556-018-0045-z
25.
JasperK, StilesB, McDonaldF, et al.Practical management of oligometastatic non–small-cell lung cancer. J Clin Oncol, 2022; 40(6):635–641; doi: 10.1200/jco.21.01719
26.
JiangK, YinX, ZhangQ, et al.STC2 activates PRMT5 to induce radioresistance through DNA damage repair and ferroptosis pathways in esophageal squamous cell carcinoma. Redox Biol, 2023; 60:102626; doi: 10.1016/j.redox.2023.102626
27.
JinT, YangL, ChangC, et al.HnRNPA2B1 ISGylation regulates M6A‐Tagged MRNA selective export via ALYREF/NXF1 complex to foster breast cancer development. Adv Sci (Weinh), 2024; 11(24):e2307639; doi: 10.1002/advs.202307639
28.
KhanSU, FatimaK, AishaS, et al.Redox balance and autophagy regulation in cancer progression and their therapeutic perspective. Med Oncol, 2022; 40(1):12; doi: 10.1007/s12032-022-01871-0
29.
KimY, ParkK, KimYJ, et al.Immunomodulation of HDAC inhibitor entinostat potentiates the anticancer effects of radiation and PD-1 Blockade in the murine lewis lung carcinoma model. Int J Mol Sci, 2022; 23(24):15539; doi: 10.3390/ijms232415539
30.
KlionskyDJ, Abdel-AzizAK, AbdelfatahS, et al.Guidelines for the use and interpretation of assays for monitoring autophagy (4th Edition)1. Autophagy, 2021; 17(1):1–382; doi: 10.1080/15548627.2020.1797280
31.
KoutroumpakisE, DeswalA, YusufSW, et al.Radiation-Induced cardiovascular disease: Mechanisms, prevention, and treatment. Curr Oncol Rep, 2022; 24(5):543–553; doi: 10.1007/s11912-022-01238-8
32.
LeeSM, SchulzC, PrabhashK, et al.First-Line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a Platinum-Containing Regimen (IPSOS): A phase 3, global, multicentre, open-label, randomised controlled study. Lancet, 2023; 402(10400):451–463; doi: 10.1016/s0140-6736(23)00774-2
33.
LiH, ChenY, DingM, et al.Pectolinarigenin attenuates hepatic Ischemia/reperfusion injury via activation of the PI3K/AKT/Nrf2 signaling pathway. Chem Biol Interact, 2023a;386:110763; doi: 10.1016/j.cbi.2023.110763
34.
LiY, GaoY, JiangX, et al.SAMHD1 silencing cooperates with radiotherapy to enhance anti-tumor immunity through IFI16-STING pathway in lung adenocarcinoma. J Transl Med, 2022b;20(1):628; doi: 10.1186/s12967-022-03844-3
35.
LiK, GongQ, XiangX-D, et al.HNRNPA2B1-Mediated M6A modification of LncRNA MEG3 facilitates tumorigenesis and metastasis of non-small cell lung cancer by regulating MiR-21-5p/PTEN Axis. J Transl Med, 2023b;21(1):382; doi: 10.1186/s12967-023-04190-8
36.
LiQ, WangR, YangZ, et al.Molecular profiling of human non-small cell lung cancer by single-cell RNA-Seq. Genome Med, 2022a;14(1):87; doi: 10.1186/s13073-022-01089-9
37.
LiY, XuB, RenX, et al.Inhibition of CISD2 promotes ferroptosis through ferritinophagy-mediated ferritin turnover and regulation of P62–Keap1–NRF2 pathway. Cell Mol Biol Lett, 2022c;27(1):81; doi: 10.1186/s11658-022-00383-z
38.
LiuH, LiD, SunL, et al.Interaction of LncRNA MIR100HG with HnRNPA2B1 facilitates M6A-dependent stabilization of TCF7L2 MRNA and colorectal cancer progression. Mol Cancer, 2022a;21(1):74; doi: 10.1186/s12943-022-01555-3
39.
LiuZ-X, LiL-M, SunH-L, et al.Link between M6A modification and cancers. Front Bioeng Biotechnol, 2018; 6:89; doi: 10.3389/fbioe.2018.00089
40.
LiuY, LuT, ZhangC, et al.Activation of YAP attenuates hepatic damage and fibrosis in liver ischemia-reperfusion injury. J Hepatol, 2019; 71(4):719–730; doi: 10.1016/j.jhep.2019.05.029
41.
LiuW, ZhengL, ZhangR, et al.Circ-ZEB1 promotes PIK3CA expression by silencing MiR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma. Mol Cancer, 2022b;21(1):72; doi: 10.1186/s12943-022-01529-5
42.
LvH, ChenK, ZhangD. Exploring the diagnostic value of blood circular RNA in atherosclerotic cardiovascular diseases by integrating bioinformatics and evidence-based medicine meta-analysis. Int J Biol Macromol, 2024; 261(Pt 1):129386; doi: 10.1016/j.ijbiomac.2024.129386
43.
LyuZJ, WangY, HuangJL, et al.Recurrent ZNF83-E293V mutation promotes bladder cancer progression through the NF-ΚB pathway via transcriptional dysregulation of S100A8. Mol Ther, 2021; 29(1):275–290; doi: 10.1016/j.ymthe.2020.09.004
44.
MiaoH, RenQ, LiH, et al.Comprehensive analysis of the autophagy-dependent ferroptosis-related gene FANCD2 in lung adenocarcinoma. BMC Cancer, 2022; 22(1):225; doi: 10.1186/s12885-022-09314-9
45.
MithoowaniH, FebbraroM. Non-Small-Cell lung cancer in 2022: A review for general practitioners in oncology. Curr Oncol, 2022; 29(3):1828–1839; doi: 10.3390/curroncol29030150
NaganoT, TachiharaM, NishimuraY. Molecular mechanisms and targeted therapies including immunotherapy for non-small cell lung cancer. Curr Cancer Drug Targets, 2019; 19(8):595–630; doi: 10.2174/1568009619666181210114559
48.
NiM, LiJ, ZhaoH, et al.BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair. Oncogene, 2021; 40(15):2711–2724; doi: 10.1038/s41388-021-01735-3
49.
NicolasE, LuciaF. Radiothérapie et Thérapies Ciblées: Risques et Opportunités. Cancer/Radiothérapie, 2022; 26(6–7):973–978; doi: 10.1016/j.canrad.2022.07.003
50.
OuyangL, YanB, LiuY, et al.The Deubiquitylase UCHL3 maintains cancer stem-like properties by stabilizing the aryl hydrocarbon receptor. Signal Transduct Target Ther, 2020; 5(1):78; doi: 10.1038/s41392-020-0181-3
51.
PassaroA, LeighlN, BlackhallF, et al.ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol, 2022; 33(5):466–487; doi: 10.1016/j.annonc.2022.02.003
52.
PatelSA, WeissJ. Advances in the treatment of non–small cell lung cancer. Clin Chest Med, 2020; 41(2):237–247; doi: 10.1016/j.ccm.2020.02.010
53.
PengX, YangR, PengW, et al.Overexpression of LINC00551 promotes autophagy-dependent ferroptosis of lung adenocarcinoma via upregulating DDIT4 by sponging MiR-4328. PeerJ, 2022; 10:e14180; doi: 10.7717/peerj.14180
54.
QiY, YaoR, ZhangW, et al.KAT1 Triggers YTHDF2-Mediated ITGB1 MRNA Instability to Alleviate the Progression of Diabetic Retinopathy. Pharmacol Res, 2021; 170:105713; doi: 10.1016/j.phrs.2021.105713
55.
QiuF-S, HeJ-Q, ZhongY-S, et al.Implications of M6A Methylation and microbiota interaction in non-small cell lung cancer: From basics to therapeutics. Front Cell Infect Microbiol, 2022; 12:972655; doi: 10.3389/fcimb.2022.972655
56.
RitchieME, PhipsonB, WuD, et al.Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 2015; 43(7):e47–e47; doi: 10.1093/nar/gkv007
57.
RongY, FanJ, JiC, et al.USP11 regulates autophagy-dependent ferroptosis after spinal cord ischemia-reperfusion injury by Deubiquitinating Beclin 1. Cell Death Differ, 2022; 29(6):1164–1175; doi: 10.1038/s41418-021-00907-8
58.
SchoenfeldJD, Giobbie-HurderA, RanasingheS, et al.Durvalumab plus Tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: An open-label, multicentre, randomised, phase 2 trial. Lancet Oncol, 2022; 23(2):279–291; doi: 10.1016/s1470-2045(21)00658-6
59.
ShangS, LiuJ, VermaV, et al.Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: Challenges and updates. Cancer Commun (Lond), 2021; 41(11):1086–1099; doi: 10.1002/cac2.12226
60.
ShibataT, CaoD-Y, DarTB, et al.MiR766-3p and MiR124-3p dictate drug resistance and clinical outcome in HNSCC. Cancers (Basel), 2022; 14(21):5273; doi: 10.3390/cancers14215273
61.
SolomonBJ, BauerTM, MokTSK, et al.Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-Positive non-small-cell lung cancer: Updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med, 2023; 11(4):354–366; doi: 10.1016/s2213-2600(22)00437-4
62.
StockwellBR, Friedmann AngeliJP, BayirH, et al.Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell, 2017; 171(2):273–285; doi: 10.1016/j.cell.2017.09.021
63.
SunC, GaoW, LiuJ, et al.FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer. Respir Res, 2020; 21(1):210; doi: 10.1186/s12931-020-01477-y
64.
TsaiCJ, YangJT, ShaverdianN, et al.; CURB Study Group. Standard-of-Care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] Oligoprogression): An open-label, randomised, controlled, phase 2 study. Lancet, 2024; 403(10422):171–182; doi: 10.1016/s0140-6736(23)01857-3
65.
van den BentMJ, TesileanuCMS, WickW, et al.Adjuvant and concurrent temozolomide for 1p/19q Non-Co-Deleted Anaplastic Glioma (CATNON; EORTC Study 26053-22054): Second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol, 2021; 22(6):813–823; doi: 10.1016/s1470-2045(21)00090-5
66.
WangQ, ChenC, DingQ, et al.METTL3-Mediated M6A modification of HDGF MRNA promotes gastric cancer progression and has prognostic significance. Gut, 2020; 69(7):1193–1205; doi: 10.1136/gutjnl-2019-319639
67.
WangX, FanX, ZhangJ, et al.HnRNPA2B1 represses the disassembly of arsenite-induced stress granules and is essential for male fertility. Cell Rep, 2024b;43(2):113769; doi: 10.1016/j.celrep.2024.113769
68.
WangY, MengL, MengS, et al.Flotillin-1 enhances radioresistance through reducing radiation-induced DNA damage and promoting immune escape via STING signaling pathway in non-small cell lung cancer. Cancer Biol Ther, 2023; 24(1):2203332; doi: 10.1080/15384047.2023.2203332
69.
WangY, YangX, LiN-J, et al.Leptomeningeal metastases in non-small cell lung cancer: Diagnosis and treatment. Lung Cancer, 2022; 174:1–13; doi: 10.1016/j.lungcan.2022.09.013
70.
WangJ, ZhangJ, LiuH, et al.N6‐methyladenosine reader HnRNPA2B1 recognizes and stabilizes NEAT1 to confer chemoresistance in gastric Cancer. Cancer Commun (Lond), 2024a;44(4):469–490; doi: 10.1002/cac2.12534
71.
YangZ, WangT, WuD, et al.RNA N6-Methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer. J Exp Clin Cancer Res, 2020; 39(1):203; doi: 10.1186/s13046-020-01714-8
72.
YangY, ZhangY, FengT, et al.HNRNPA2B1 Induces Cell Proliferation and Acts as Biomarker in Breast Cancer. Cancer Biomark, 2024; 40(3–4):285–296; doi: 10.3233/cbm-230576
73.
ZhangT, GuanG, ZhangJ, et al.E2F1‐mediated AUF1 upregulation promotes HCC development and enhances drug resistance via stabilization of AKR1B10. Cancer Sci, 2022b;113(4):1154–1167; doi: 10.1111/cas.15272
74.
ZhangM, LeiM, QinS, et al.Crystal structure of the BRPF2 PWWP domain in complex with DNA reveals a different binding mode than the HDGF family of PWWP domains. Biochim Biophys Acta Gene Regul Mech, 2021; 1864(3):194688; doi: 10.1016/j.bbagrm.2021.194688
75.
ZhangG, LiuZ, ChenY, et al.High serum HDGF levels are predictive of bone metastasis and unfavorable prognosis in non-small cell lung cancer. Tohoku J Exp Med, 2017; 242(2):101–108; doi: 10.1620/tjem.242.101
76.
ZhangR, ShenS, WeiY, et al.A large-scale genome-wide gene-gene interaction study of lung cancer susceptibility in Europeans with a trans-ethnic validation in Asians. J Thorac Oncol, 2022a;17(8):974–990; doi: 10.1016/j.jtho.2022.04.011
77.
ZhangY, WangD, WuD, et al.Long noncoding RNA KCNMB2-AS1 stabilized by N6-Methyladenosine modification promotes cervical cancer growth through acting as a competing endogenous RNA. Cell Transplant, 2020b;29:963689720964382; doi: 10.1177/0963689720964382
78.
ZhangQ, ZhangC, GeJ, et al.Ameliorative effects of resveratrol against cadmium-induced nephrotoxicityviamodulating nuclear xenobiotic receptor response and PINK1/Parkin-Mediated mitophagy. Food Funct, 2020a;11(2):1856–1868; doi: 10.1039/c9fo02287b
79.
ZhangX, ZhaoY, KongP, et al.Expression of CircZNF609 Is down-regulated in colorectal cancer tissue and promotes apoptosis in colorectal cancer cells by upregulating P53. Med Sci Monit, 2019; 25:5977–5985; doi: 10.1265/9/msm.915926
80.
ZhengL, ChenX, YinQ, et al.RNA-M6A modification of HDGF mediated by Mettl3 aggravates the progression of atherosclerosis by regulating macrophages polarization via energy metabolism reprogramming. Biochem Biophys Res Commun, 2022; 635:120–127; doi: 10.1016/j.bbrc.2022.10.032
81.
ZhongG, WangQ, WangY, et al.ScRNA-Seq reveals ATPIF1 activity in control of T cell antitumor activity. OncoImmunology, 2022; 11(1):2114740; doi: 10.1080/2162402x.2022.2114740
82.
ZhuZ, HuoF, ZhangJ, et al.Crosstalk between M6A modification and alternative splicing during cancer progression. Clin Transl Med, 2023; 13(10):e1460; doi: 10.1002/ctm2.1460
83.
ZhuS, ZhuZ, MaA-H, et al.Preclinical models for bladder cancer research. Hematol Oncol Clin North Am, 2021; 35(3):613–632; doi: 10.1016/j.hoc.2021.02.007
84.
ZouJ, WangL, TangH, et al.Ferroptosis in non-small cell lung cancer: Progression and therapeutic potential on it. Int J Mol Sci, 2021; 22(24):13335; doi: 10.3390/ijms222413335
85.
ZuoX, ChenZ, GaoW, et al.M6A-Mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma. J Hematol Oncol, 2020; 13(1):5; doi: 10.1186/s13045-019-0839-x
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
